Tempus AI, Inc. - Class A Common Stock (TEM)

Second-quarter results arrived with numbers that caused investors to feel increasingly bullish.

Tempus AI Inc (TEM) reported strong Q2 2025 results, beating revenue and EPS estimates with 89.6% YoY growth. Stock surged 8.7% pre-market on raised guidance and AI-driven expansion.

Tempus AI beat Q2 estimates with 90% revenue growth, narrowed losses, and a raised 2025 outlook driven by strong genomics and data services gains.

Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in their positions.

This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

On Wednesday, Cathie Wood-led Ark Invest executed significant trades, including substantial purchases in Tempus AI Inc. (NASDAQ:TEM), NVIDIA Corp. (NASDAQ:NVDA), 3iQ Ether Stakin

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software.

On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc. (NASDAQ:TEM), Coinbase Global Inc. (NASDAQ:COIN), Robinhood Markets Inc. (NASDAQ

An AI health care stock backed by Nancy Pelosi and Cathie Wood is drawing criticism from Jim Cramer.

Apple's $60 billion cash pile and a rare executive shake-up reignite speculation: will the tech giant finally go on an AI buying spree to catch up with rivals?

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.

On Wednesday, the Cathie Wood-led Ark Invest made a significant move by purchasing a substantial number of shares in Tempus AI Inc. (NASDAQ:TEM) and selling shares of Block Inc. (NYSE:XYZ).

Cathie Wood's Ark Investment Management has filed plans to launch four new exchange-traded funds designed to offer downside protection for investors in its flagship ARK Innovation ETF (BATS: ARKK), while placing a cap on potential gains.

10 worst performing large-cap stocks in holiday-shortened week, including Centene Corp, Molina Healthcare, and Circle Internet Group.